| No. |
Research Title |
Investigator |
Status |
| 1 |
AEGIS II – A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subject with Acute Coronary Syndrome |
Dato’ Sri Dr. Haji Azhari Rosman |
Enrollment |
| 2 |
APPIRED III – Preventing Oxidative Stress Induced Ischemic Injury and Systemic Inflammation Complications During and After Invasive Cardiac Surgery with Alkaline Phosphatase |
Dr. Pau Kiew Kong |
Enrollment |
| 3 |
ABILITY DIABETES – Randomized Comparison of Abluminus DES+ Sirolimus-Eluting Stents versus Everolimus-Eluting Stents in Coronary Artery Disease Patients with Diebetes Mellitus Global. |
Dato’ Dr. Amin Ariff Nuruddin |
Enrollment |
| 4 |
COMBINE-INTERVENE – COMBINEd Ischemia and Vulnerable Plaque Percutaneous INTERVENtion to Reduce Cardiovascular Events. |
Dato’ Dr. Amin Ariff Nuruddin |
Enrollment |
| 5 |
LEADR: Lead Evaluation for Defibrillation and Reliability |
Dr. Surinder Kaur Khelae |
Enrollment |
| 6 |
CTO Registry using the HYBRID CTO ALGORITHM at IJN. (Device : Crossboss & Stingray) |
Datuk Dr. Shaiful Azmi Yahaya |
Enrollment |
| 7 |
FINEARTS – A multicentre, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of finerenone on morbidity and mortality in participants with heart failure(NYHA II-IV) and EF ≥40% |
Dr. Teoh Chee Kiang |
Enrollment |
| 8 |
DEDICATE REGISTRY – A Post Market Registry of Abluminum® Sirolimus Eluting Coronary Stent System for Percutaneous Intervention in Patients with Diabetic Mellitus |
Dato’ Sri Dr. Haji Azhari Rosman |
Enrollment |
| 9 |
GSR DEFINE: Global SYMPLICITY Registry (GSR) Denervation Findings in Real World (DEFINE) is referred to as the GSR DEFINE study |
Dato’ Dr. Amin Ariff Nuruddin |
Enrollment |
| 10 |
FIM-IBS – A Prospective, Non-randomized, Open lable, Non-comparative, First-in-Man Study to Evaluate the Feasibility and Safety of Sirolimus-eluting Iron Bioresorbable Coronary Scaffold System |
Datuk Dr. Shaiful Azmi Yahaya |
Enrollment |
| 11 |
ZEUS-Effects of ziltivekimab versus placebo on cardiovascular outcomes in participants with established atherosclerotic cardiovascular disease, chronic kidney disease and systemic inflammation |
Dato’ Sri Dr. Haji Azhari Rosman |
Enrollment |
| 12 |
MID-Q Response |
Datuk Dr. Azlan Hussin |
Enrollment |
| 13 |
NEOS-APAC-Asian Pacific post-market clinical follow-up study in patients with acute or chronic aortic dissection or aortic aneurysm treated with E-vita OPEN NEO |
Mr. Paneer Selvam |
Enrollment |
| 14 |
RESTORE: A Prospective, Multicenter, Single-Arm, Open-Label, Phase 4 Study of the Effects of Selexipag on Right Ventricular Remodeling in Pulmonary Arterial Hypertension Assessed by Cardiac Magnetic Resonance Imaging |
Dr. Geetha A/P Kandavello @ Kandhavel |
Enrollment |
| 15 |
TOMORROW – A Multicenter, Open-label, Randomized, Event-driven Study to Assess Efficacy, Safety and Pharmacokinetics of Macitentan Versus Standard of Care in Children with Pulmonary Arterial Hypertension |
Dr. Geetha A/P Kandavello @ Kandhavel |
Enrollment |
| 16 |
VFAHF STUDY – Ventricle from Atrium Heart Failure Clinical Study (VFAHF) |
Datuk Dr. Azlan Hussin |
Enrollment |
| 17 |
SALTO – A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group, Event-Driven, Group-Sequential Study with Open-Label Extension Period to Assess the Efficacy and Safety of Selexipag as Add-On Treatment to Standard of Care in Children Aged ≥2 to <18 years with Pulmonary Arterial Hypertension |
Dr. Geetha A/P Kandavello @ Kandhavel |
Enrollment |
| 18 |
SCORE REGISTRY: Sequent® SCB ‘’All Comers’’ Post Market Clinical Follow up (PMCF) |
Dato’ Dr. Amin Ariff Nuruddin |
Enrollment |
| 19 |
STRIDE: Effects of semaglutide on functional capacity in patients withtype 2 diabetes and peripheral arterial disease |
Datuk Dr. Shaiful Azmi Yahaya |
Enrollment |
| 20 |
PRIME-FFR: Prognostic impact of lesion-specific hemodynamic index and disease characteristics in patients with coronary artery disease assessed by fractional flow reserve |
Dato’ Sri Dr. Haji Azhari Rosman |
Enrollment |
| |
|
|
|
| No. |
Research Title |
Investigator |
Status |
| 1 |
BIOLUX P-III REGISTRY: BIOTRONIK-A Prospective, International, Multi-Centre, Post-Market All-Comers Registry To Assess The Clinical Performance Of The Passeo-18 Lux Paclitaxel Releasing Balloon Catheter In Infraguinal Arteries -III |
Datuk Dr. Shaiful Azmi Yahaya |
Follow Up |
| 2 |
Meres-1 Extend: A Prospective, Multinational, Multicenter, Single Arm, Open Label, Pilot Clinical Study Of Meres100 Sirolimus Eluting Bioresorbable Vascular Scaffold System In The Treatment Of De-Novo Native Coronary Artery Lesions |
Dato’ Dr. Amin Ariff Nuruddin |
Follow Up |
| 3 |
ABSORB BVS: Comparative Study In Real World Use Of The ABSORB Bioresorbable Vascular Scaffold In De Novo Coronary Artery Disease Among Diabetes And Non-Diabetes Patient In Institut Jantung Negara, Malaysia: A Prospective Post-Marketing Single-Center Registry |
Datuk Dr. Shaiful Azmi Yahaya |
Follow Up |
| 4 |
CONSEQUENT ALL COMERS: Clinical PMCF on Peripheral Arteries treated with SeQuent® Please OTW Paclitaxel Coated Balloon Catheter in an All Comer Patient Population |
Datuk Dr. Shaiful Azmi Yahaya |
Follow Up |
| 5 |
ISCHEMIA – International Study of Comparative Health Effectiveness With Medical and Invasive Approaches |
Datuk Dr. Ahmad Khairuddin Mohamed Yusof |
Follow Up |
| 6 |
The EASTBOURNE Registry: The All-comers Sirolimus-coated balloon European registry. |
Dato’ Dr. Amin Ariff Nuruddin |
Follow Up |
| 7 |
SCB DE-NOVO STUDY: Treatment of coronary de-novo stenosis by a sirolimus coated balloon or a paclitaxel coated balloon catheter |
Dato’ Dr. Amin Ariff Nuruddin |
Follow Up |
| 8 |
BIOSOLVE-IV REGISTRY: Safety And Performance In De Novo Lesion Of Native Coronary Arteries With Magmaris – Registry Data |
Dato’ Dr. Amin Ariff Nuruddin |
Follow Up |
| 9 |
MYHF: Malaysian National Heart Failure Registry |
Dato’ Dr. Azmee Bin Mohd Ghazi |
Follow Up |
| 10 |
SELECT STUDY: Semaglutide effects on cardiovascular outcomes in people with overweight or obesity |
Dato’ Sri Dr. Haji Azhari Rosman |
Follow Up |
| 11 |
BGSAMIRP: Blood-based Genomic Signatures in Acute Myocardial Infarction Risk Prediction |
Dato’ Dr. Amin Ariff Nuruddin |
Follow Up |
| 12 |
CAAN-AF: Cardiac Resynchronization therapy (CRT) And AV Node ablation in Atrial Fibrillation |
Datuk Dr. Azlan Hussin |
Follow Up |
| 13 |
PROTECT-ICD Trial: Programmed Ventricular Stimulation to Risk Stratify for Early Cardioverter-Defibrillator (ICD) Implantation to Prevent Tachyarrhythmias Following Acute Myocardial Infarction |
Dr. Geetha A/P Kandavello @ Kandhavel |
Follow Up |
| 14 |
CRYO AF GLOBAL REGISTRY |
Dr. Surinder Kaur Khelae |
Follow Up |
| 15 |
A DUE: Prospective, multi-center, double-blind, randomized, active-controlled, triple-dummy, parallel-group, group-sequential, adaptive Phase 3 clinical study to compare the efficacy and safety of macitentan and tadalafil monotherapies with the corresponding fixed dose combination in subjects with pulmonary arterial hypertension (PAH), followed by an open-label treatment period with macitentan and tadalafil fixed dose combination therapy |
Dr. Geetha A/P Kandavello @ Kandhavel |
Follow Up |
| 16 |
BIOFLOW-DAPT: BIOTRONIK – A Prospective, Randomized, Multi-center Study to Assess the SaFety of the Orsiro Mission Stent compared to the ResoLute Onyx Stent in Subjects at High Risk for Bleeding in combination With 1-month Dual Antiplatelet Therapy (DAPT) |
Datuk Dr. Shaiful Azmi Yahaya |
Follow Up |
| 17 |
MICRA AV: Product Surveillance Registry (PSR) |
Datuk Dr. Azlan Hussin |
Follow Up |
